Schedule a Meeting

LumineticsCore Logo
LumineticsCore is an Al diagnostic system that autonomously diagnoses diabetic retinopathy (including macular edema) in people living with diabetes.

  • Diagnostic results at the point-of-care
  • No need for specialist overread or telemedicine call backs
  • A simple user interface
  • Customized workflow integration solutions

The Problem: Every Year, Over 60,000 People Go Blind from Diabetic Retinopathy

How LumineticsCore Works

1

Using a fundus camera, the trained operator captures two images per eye

2

The images are submitted to LumineticsCore

background graphics background graphics background graphics

3

LumineticsCore analyzes images for signs of diabetic retinopathy (including macular edema), providing results in less than a minute

Results

No diabetic retinopathy detected: Retest in 12 Months

Results

Diabetic retinopathy detected: Refer to an eye care professional

LumineticsCore™ – How It Works | Play Video

Digital Diagnostics LumineticsCore

Our Approach to AI Driven Diagnostics

AI the Right Way™

LumineticsCore™ is modeled to look for and make decisions based on the same clinical disease detectors that eye care specialists would use.

  • Diagnostic AI built on an ethical foundation
  • Diagnostic results at the point-of-care
  • Infinitely scalable

High Performance in a
Real-World Clinical Setting

Safety

LumineticsCore was validated against patient outcomes using a surrogate outcome standard to keep patient safety the main priority. 

Effective

In our pivotal clinical trial, LumineticsCore avoided 91% of unnecessary specialty visits by providing a diagnostic result that is negative for diabetic retinopathy (including macular edema) at the point-of-care.

Equitable

LumineticsCore has been trained and validated on over 2M images to mitigate bias and ensure the system works equally well for all people, regardless of sex, race, or ethnicity. For more information, read the LumineticsCore pivotal trial.

LumineticsCore Patient #1 and Operator

Who is LumineticsCore for?

Digital Diagnostics is impacting patient care across the globe.

LumineticsCore Patient #2 and Operator Positive Result

Front-Line Care Providers

LumineticsCore™ is for medical professionals to provide patients with a rigorously validated and ethically designed diagnostic system. LumineticsCore results are provided at the point-of-care, allowing for more comprehensive diabetes care and improved performance with the eye exam for diabetes quality measures. 

Ophthalmologists & Optometrists

LumineticsCore™ is for eye care providers to help address disparities and improve equity in care as part of the eye exam for people with diabetes. LumineticsCore results can lead to more actionable referrals by identifying patients with diabetic retinopathy who are not already under the care of an eye care provider. This can help increase access for the patients who are most likely to need timely vision-saving interventions.

Digital Diagnostics LumineticsCore Patient Exam
Operator showing document

Payor Community

LumineticsCore™ is for payors to improve healthcare efficiency and access to care for enrollees while supporting the Patient Centered Medical Home (PCMH).

  • Cost savings over the life-time of care
  • Prevent blindness through early disease detection
  • 100% compliance for diabetic retinopathy exams saves > $5B/year

Patients

LumineticsCore™ is for adults (22 years of age or older) diagnosed with diabetes who have not been previously diagnosed with diabetic retinopathy and are not currently under the care of an eye care specialist. LumineticsCore is installed at point-of-care locations to increase patient access and convenience.

LumineticsCore Patient

Indications for Use

LumineticsCore™ is intended for use by health care providers to automatically detect more than mild diabetic retinopathy (mtmDR) in adults (22 years of age or older) diagnosed with diabetes who have not been previously diagnosed with diabetic retinopathy. LumineticsCore™ is indicated for use with the Topcon NW400

Tarzana Treatment Centers

"This AI technology has improved satisfaction for both patients and the clinical team by providing clinicians with real-time data to manage diabetes more effectively. Support staff feel a sense of pride and accomplishment when explaining the technology to patients. The integration of LumineticsCore with EPIC has made our busy clinics into a convenient one stop shop. What we want in Medicine!"

Michael P. Soles, MD, Medical Champion Tarzana Treatment Centers

Johns Creek Primary Care

“LumineticsCore™ really is cutting-edge technology that helps me market to patients, prevent vision loss from diabetes, and improve my quality scores”

Lee Herman, MD, FACP Johns Creek Primary Care

Cahaba Medical Care

“An immediate point-of-care result is great to close the communications loop with the patient. The more you can get done when the patient is at the visit is better.”

John B. Waits, MD, FAAFP, Chief Executive Officer Cahaba Medical Care

Tarzana Treatment Centers

“Patients are empowered when they see how their retina looks and what a worse outcome prognosis could be. In this case, the patient was so motivated to not lose his sight that he dropped his HbA1c within three months. We are now discussing decreasing daily insulin dosages.”

Tarzana Treatment Centers, Provider Overseeing Diabetes Care

Tarzana Treatment Center

“It’s been a godsend for us.”

Christian Espinoza, Director of Clinic Operations Tarzana Treatment Centers

Zufall Health

“The identification of organ damage also provides crucial feedback for the patient and medical team regarding the need for intensifying or improving overall diabetes care.”

Douglas Bishop, MD Family Medicine Provider at Zufall Health Center

University Medical Center

“It’s a better and more efficient system that allows us to do more exams.”

LumineticsCore™ Operator at UMC

OSF Healthcare

“Nearly one-quarter of all patients with diabetes who received the [LumineticsCore] exam tested positive for diabetic retinopathy. The AI can see the early changes of diabetic retinopathy that we may not be able to see with our own eyes.There’s nothing as good as prevention.”

Mark Meeker, DO, VP of Community Medicine at OSF HealthCare

LumineticsCore FAQ

What is LumineticsCore™?

LumineticsCore™ detects more than mild diabetic retinopathy, which is ETDRS level 35 or higher (including macular edema) at point-of-care to provide the patient with a diagnostic report without a physician evaluation. After completing a rigorous prospective, preregistered clinical trial at primary care sites across the country, LumineticsCore™ became the first FDA De Novo-cleared AI diagnostic system to make a diagnosis without physician input. LumineticsCore™ is deployed in point-of-care offices across the globe.

What are the indications for LumineticsCore™?

LumineticsCore™ is intended for use by health care providers to automatically detect more than mild diabetic retinopathy, which is ETDRS level 35 or higher in adults (22 years of age or older) diagnosed with diabetes who have not been previously diagnosed with diabetic retinopathy.

Warnings

  • LumineticsCore™ does not replace a full eye exam, but it will find diabetic retinopathy  that needs to be examined by an eye doctor. Patients who have blurry vision or other symptoms of vision loss should see an eye doctor right away.
  • While LumineticsCore™ is reliable, it is not perfect. It is possible that LumineticsCore™ is unable to detect disease that is present, or possibly give a false positive diagnosis.

To review the LumineticsCore™ Indications for Use click here.

How does LumineticsCore™ work?

Using a fundus camera, an operator captures high-quality images of the patients’ eyes. The images are then submitted to LumineticsCore™ where they are analyzed for signs of diabetic retinopathy. A diagnostic result is provided in within the patient encounter at point-of-care with follow up instructions for the patient based on diagnostic outcome. If disease is detected, the patient is referred to an eye care professional during their appointment where they received their diagnosis, which increases the chances a patient will follow through with the referral. If there is no disease detected the patient is advised to get retested in 12 months.

Who is LumineticsCore™ for?

Patients

LumineticsCore is for adults (22 years of age or older) diagnosed with diabetes who have not been previously diagnosed with diabetic retinopathy and are not currently under the care of an eye care specialist. LumineticsCore™ is installed at point-of-care locations to increase patient access and convenience.

Providers

LumineticsCore is for medical professionals who want to provide patients with rigorously validated and ethically designed diagnostic results at the point-of-care, allowing for more comprehensive diabetes care and improved performance with eye exams for people with diabetes quality measures.

Payors

LumineticsCore is for payors to improve healthcare efficiency and access to care for enrollees while supporting the Patient Centered Medical Home (PCMH).

Eye Care Providers

LumineticsCore is for eye care providers to help address disparities and improve equity in care as part of the diabetic eye exam delivery model. LumineticsCore results can lead to more actionable referrals, identifying patients with diabetes not already under the care of an eye care provider, who are most likely to need timely vision saving interventions.

What is autonomous AI?

Autonomous AI is a technology that can make clinical and diagnostic decisions that impact patient care without the need for physician involvement.